NRx Pharmaceuticals advances manufacturing to 1M-unit batches ahead of a potential summer 2026 KETAFREE approval filing.
NRx Pharmaceuticals reported progress in scaling production of preservative-free ketamine, targeting 1M-unit batches by mid-2026. The company plans to file for FDA approval of KETAFREE in summer 2026, citing regulatory and manufacturing milestones in Q1 2026.
Management highlighted advancements in both regulatory pathways and commercial manufacturing during the quarter. The company also noted NRX-101’s entry into a registrational trial, reinforcing its pipeline expansion.
Shares showed limited immediate reaction to the update, focusing on long-term regulatory and production timelines.